Do ESR1 (rs2234693, rs9340799) and OPG (rs2073618) variants increase osteoporosis risk when estradiol is low?

The relationship between estrogen receptor 1 (ESR1) polymorphisms, osteoprotegerin (OPG) variants, and bone health highlights the complex interplay between genetic susceptibility and hormonal status.

Clinical evidence and genetic associations

• Early candidate-gene studies linked ESR1 intronic polymorphisms (PvuII/rs2234693 and XbaI/rs9340799) and the OPG/TNFRSF11B variant (rs2073618) to bone mineral density (BMD) variations and postmenopausal osteoporosis risk.
• However, contemporary large-scale meta-analyses utilizing rigorous statistical controls—such as false-positive report probability (FPRP) and Bayesian false-finding metrics—suggest these direct, standalone associations are weak, inconsistent across populations, and highly likely to represent false-positive findings of negligible clinical significance on their own.

Mechanistic explanations

• Estradiol normally binds to estrogen receptor-alpha (ESR1) to upregulate the expression of OPG, which acts as a decoy receptor for receptor activator of nuclear factor kappa-B ligand (RANKL). This suppresses osteoclastogenesis and limits bone resorption.
• In estrogen-deficient states, decreased ESR1 signaling leads to a drop in OPG expression, elevating the RANKL/OPG ratio and promoting bone breakdown.
• Epistatic (gene-gene) interaction studies indicate that the phenotypic expression of OPG variants is modulated by ESR1 genotypes. Under low-estradiol conditions, this pathway's protective capacity is compromised, meaning individuals harboring risk-associated variants in both genes experience a compounded susceptibility to bone loss.

Bottom line

• While ESR1 (rs2234693, rs9340799) and OPG (rs2073618) variants have weak, low-confidence direct effects on bone density in the general population, they act as context-dependent genetic modifiers that interact to accelerate bone loss when circulating estradiol levels are low.